Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 1
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT04282070
- Locations
- 🇨🇳
Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China
Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2020-04-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04260373
- Locations
- 🇨🇳
First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China
The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04229433
- Locations
- 🇨🇳
Zhejing Provincial People's Hospital, Hangzhou, Zhejiang, China
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 690
- Registration Number
- NCT04229615
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT04228601
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 762
- Registration Number
- NCT04203485
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04200235
- Locations
- 🇨🇳
Beijing children's hospital, capital medical university, Beijing, Beijing, China
Food Effect Study of DDO-3055 Tablets in Healthy Subjects
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04197778
- Locations
- 🇨🇳
Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04193319
- Locations
- 🇨🇳
Early Cancer Research Center of Hunan Cancer Hospital, Hunan, Hunan, China
A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT04180982
© Copyright 2024. All Rights Reserved by MedPath